Baker Bros. Advisors LP Chinook Therapeutics, Inc. Transaction History

Baker Bros. Advisors LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$21.53 - $26.8 $23.2 Million - $28.9 Million	-1,078,900 Reduced 42.58%	1,455,202 $33.7 Million
Q2 2022 Aug 15, 2022	BUY	$12.59 - $18.8 $2.52 Million - $3.76 Million	200,000 Added 8.57%	2,534,102 $44.3 Million
Q4 2021 Feb 14, 2022	BUY	$10.69 - $16.83 $4.61 Million - $7.25 Million	431,033 Added 22.65%	2,334,102 $38.1 Million
Q3 2021 Nov 15, 2021	BUY	$11.5 - $14.86 $9.46 Million - $12.2 Million	822,676 Added 76.15%	1,903,069 $24.3 Million
Q2 2021 Aug 16, 2021	BUY	$13.6 - $18.98 $4.51 Million - $6.3 Million	331,700 Added 44.3%	1,080,393 $15.3 Million
Q4 2020 Feb 16, 2021	BUY	$11.9 - $20.91 $8.91 Million - $15.7 Million	748,693 New	748,693 $11.9 Million

234K

Ticker KDNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,896,300
Description
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...

Get notified when there are updates to the investment portfolio of Baker Bros. Advisors LP, based on Form 13F filings with the SEC.

Stay updated on Baker Bros. Advisors LP with notifications on news.